NASDAQ:FNCH Finch Therapeutics Group (FNCH) Stock Price, News & Analysis $7.30 0.00 (0.00%) As of 09/24/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsInsider TradesSEC Filings About Finch Therapeutics Group Stock (NASDAQ:FNCH) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get FNCH alerts:Sign Up Key Stats Today's Range$7.30▼$7.3050-Day Range$7.30▼$7.3052-Week Range$2.00▼$16.10VolumeN/AAverage Volume5,025 shsMarket Capitalization$11.72 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Finch Therapeutics Group, Inc. is a biotechnology company focused on developing microbiome-based therapies for diseases associated with disruptions in the human gut microbiome. The company uses its Human-First Discovery platform, which combines clinical data, microbial analysis and biological research to identify therapeutic candidates derived from or designed to influence the microbiome. Finch’s lead development program has been FIN-211, an orally administered microbiome therapy investigated for autism spectrum disorder, particularly in patients experiencing gastrointestinal symptoms. The company has also historically pursued microbiome-based candidates for inflammatory and gastrointestinal diseases, including programs targeting conditions such as Crohn’s disease and ulcerative colitis. Founded in Cambridge, Massachusetts, Finch has conducted its research and clinical development activities primarily in the United States. Its programs and corporate strategy have changed over time as the company has restructured its pipeline, and information about the status of individual candidates may vary by reporting period. Finch’s work has centered on translating insights from human microbiome research into potential prescription therapies.AI Generated. May Contain Errors. Read More Receive FNCH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Finch Therapeutics Group and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. FNCH Stock News HeadlinesBoston biotech company files for Chapter 11 amid financial reorganizationMarch 23, 2026 | msn.comWhat Makes Finch Therapeutics (FNCH) a Worthy Investment?December 11, 2025 | msn.comHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. One day it's a ceasefire, the next it's bombs again. The back and forth may be masking a bigger story most investors are missing. See the real reason this conflict may never fully end. | Banyan Hill Publishing (Ad)FNCH - Finch Therapeutics Group Inc Price vs Fair Value - MorningstarJuly 4, 2025 | morningstar.comMFNCH Finch Therapeutics Group, Inc. - Seeking AlphaJune 24, 2025 | seekingalpha.comArquitos Capital's Largest Holdings For Q1 2025May 1, 2025 | seekingalpha.comArquitos Capital Management Q4 2024 CommentaryFebruary 5, 2025 | seekingalpha.comFinch Therapeutics Group, Inc.: Finch Announces Delisting from Nasdaq and SEC DeregistrationOctober 23, 2024 | finanznachrichten.deSee More Headlines FNCH Stock Analysis - Frequently Asked Questions How have FNCH shares performed this year? Finch Therapeutics Group's stock was trading at $13.4870 at the beginning of the year. Since then, FNCH shares have decreased by 45.9% and is now trading at $7.30. How were Finch Therapeutics Group's earnings last quarter? Finch Therapeutics Group, Inc. (NASDAQ:FNCH) posted its earnings results on Wednesday, November, 10th. The company reported ($6.30) earnings per share for the quarter, topping the consensus estimate of ($12.60) by $6.30. The company earned $11.34 million during the quarter. When did Finch Therapeutics Group's stock split? Finch Therapeutics Group shares reverse split before market open on Monday, June 12th 2023.The 1-30 reverse split was announced on Monday, June 12th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did Finch Therapeutics Group IPO? Finch Therapeutics Group (FNCH) raised $101 million in an IPO on Friday, March 19th 2021. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. BofA Securities, Jefferies and Evercore ISI acted as the underwriters for the IPO. How do I buy shares of Finch Therapeutics Group? Shares of FNCH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Finch Therapeutics Group own? Based on aggregate information from My MarketBeat watchlists, some other companies that Finch Therapeutics Group investors own include CNS Pharmaceuticals (CNSP), Allarity Therapeutics (ALLR), Aridis Pharmaceuticals (ARDS), Meta Platforms (META), NVIDIA (NVDA) and Company Calendar Last Earnings11/10/2021Today9/26/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:FNCH CIK1733257 Webwww.finchtherapeutics.com Phone617-229-6499FaxN/AEmployees190Year Founded2014Profitability EPS (Trailing Twelve Months)($8.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$74.75 million Net MarginsN/A Pretax MarginN/A Return on Equity-69.14% Return on Assets-26.92% Debt Debt-to-Equity RatioN/A Current Ratio3.87 Quick Ratio3.87 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$14.25 per share Price / Book0.51Miscellaneous Outstanding Shares1,606,000Free Float885,000Market Cap$11.72 million OptionableNo Data Beta1.18 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:FNCH) was last updated on 9/26/2026 by MarketBeat.com Staff. From Our PartnersA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | Sponsored"How Much Can I Actually Spend Each Year With $2.5M Saved?"Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...SmartAsset | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredAnalyst nicknamed “The Prophet” issues new warning for AmericaWhitney Tilson exposed a major company on 60 Minutes in an Emmy-winning investigation - the stock lost nearly ...Stansberry Research | SponsoredThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredBuffett's Final Warning: "The Dollar Is Going to Hell"On May 3rd, 2025, Warren Buffett looked at his shareholders for the last time and said: "The dollar is going t...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Finch Therapeutics Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Finch Therapeutics Group With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
